The BCL2L11 deletion polymorphism is not associated with imatinib resistance in chronic myeloid leukemia patients: meta-analysis

被引：0
|
作者：
Xu, Jinyun [1 ,2 ]
Gu, Jiaowei [2 ]
Zhao, Yan [2 ]
Meng, Huihua [1 ]
Du, Li'an [1 ]
Zhang, Ruibo [2 ]
Jiang, Hao [2 ]
Luo, Jianming [1 ]
机构：
[1] Guangxi Med Univ, Affiliated Hosp 1, Dept Pediat, Nanning, Guangxi, Peoples R China
[2] Hubei Univ Med, Taihe Hosp, Dept Pediat, Shiyan, Hubei, Peoples R China
来源：
ONCOTARGET | 2017年 / 8卷 / 58期
关键词：
BIM; chronic myeloid leukemia; tyrosine kinase inhibitor; genetic polymorphism; drug resistance; DIAGNOSED CHRONIC-PHASE; PATIENTS RECEIVING IMATINIB; FOLLOW-UP; CYTOGENETIC RESPONSES; INTRINSIC RESISTANCE; 1ST-LINE TREATMENT; TYROSINE KINASE; BIM; DASATINIB; NILOTINIB;
D O I：
10.18632/oncotarget.21154
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A common deletion polymorphism of the gene Bcl-2 like protein 11 (BCL2L11, BIM) has been reported to cause tyrosine kinase inhibitors (TKIs) resistance in several malignant tumors. However, the conclusions were not consistent in chronic myeloid leukemia (CML) individuals. In order to obtain a reliable conclusion, we systematically searched PubMed, Embase, Web of Science, Chinese Biomedical Database, and China National Knowledge Infrastructure and performed the meta-analysis. Six published articles contain 760 East Asian patients were identified from these electronic databases. The methodological quality of one included trial was high, and the others were moderate. Meta-analysis showed that the rate of TKI resistance between the BIM deletion and wild-type group were no statistical significance (OR = 1.24, 95% CI 0.79-1.95). In conclusion, BIM deletion may not a predictor of TKI resistance in CML individuals in East Asia.
引用
收藏
页码：99041 / 99048
页数：8
相关论文
共 50 条
  • [1] The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients
    Katagiri, Seiichiro
    Umezu, Tomohiro
    Ohyashiki, Junko H.
    Ohyashiki, Kazuma
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 160 (02) : 269 - 272
  • [2] BCL2L11 (BIM) Deletion Polymorphism Is Associated with Molecular Relapse after ABL Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia with Complete Molecular Response
    Katagiri, Seiichiro
    Tauchi, Tetsuzo
    Saito, Yuu
    Sugro, Tamiko
    Asano, Michiyo
    Yoshizawa, Seiichiro
    Sakuta, Juri
    Akahane, Daigo
    Tanaka, Yuko
    Furuya, Nahoko
    Ando, Keiko
    Fujimoto, Hiroaki
    Okabe, Seiichi
    Gotoh, Moritaka
    Ito, Yoshikazu
    Umezu, Tomohiro
    Ohyashiki, Junko H.
    Ohyashiki, Kazuma
    BLOOD, 2014, 124 (21)
  • [3] ASSOCIATION OF BCL2L11 (BIM) DELETION POLYMORPHISM WITH MOLECULAR RELAPSE AFTER TYROSINE KINASE INHIBITOR CESSATION IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH DEEP MOLECULAR RESPONSE
    Katagiri, S.
    Tauchi, T.
    Tanaka, Y.
    Ando, K.
    Okabe, S.
    Gotoh, M.
    Ito, Y.
    Umezu, T.
    Tadokoro, K.
    Ohyashiki, J. H.
    Ohyashiki, K.
    HAEMATOLOGICA, 2017, 102 : 442 - 442
  • [4] A deletion polymorphism in the RIZ gene is associated with increased progression of imatinib treated chronic myeloid leukemia patients
    Mir, Rashid
    Najar, Imtiyaz Ah
    Guru, Sameer
    Javaid, Jamsheed
    Yadav, Prasant
    Masroor, Mirza
    Zuberi, Mariyam
    Farooq, Shazia
    Bhat, Musadiq
    Gupta, Naresh
    Ray, Prakash Chander
    Saxena, Alpana
    LEUKEMIA & LYMPHOMA, 2017, 58 (07) : 1694 - 1701
  • [5] Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy
    Li, Xuanzong
    Zhang, Dai
    Li, Butuo
    Zou, Bing
    Wang, Shijiang
    Fan, Bingjie
    Li, Wanlong
    Yu, Jinming
    Wang, Linlin
    LUNG CANCER, 2021, 151 : 39 - 43
  • [6] Polymorphisms in Drug Transporter and Metabolism Genes Associated with Resistance to Imatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis
    Gomez, Ana Marcela Arrieta
    Diaz-Mendoza, Maria Antonia
    Lemus, Yesit Bello
    Leon-Mejia, Grethel
    Benitez, Martha Lucia Ruiz
    SCIENTIA PHARMACEUTICA, 2024, 92 (01)
  • [7] Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis
    Jiang, Zhi-Ping
    Zhao, Xie-Lan
    Takahashi, Naoto
    Angelini, Sabrina
    Dubashi, Biswajit
    Sun, Li
    Xu, Ping
    PHARMACOGENOMICS, 2017, 18 (01) : 35 - 56
  • [8] Influence of BCL2L11 polymorphism on osteonecrosis during treatment of childhood acute lymphoblastic leukemia
    Maria Plesa
    Vincent Gagné
    Sanja Glisovic
    Melissa Younan
    Bahram Sharif-Askari
    Caroline Laverdière
    Nathalie Alos
    Jean-Marie Leclerc
    Stephen E Sallan
    Donna Neuberg
    Jeffery L Kutok
    Lewis B Silverman
    Daniel Sinnett
    Maja Krajinovic
    The Pharmacogenomics Journal, 2019, 19 : 33 - 41
  • [9] Influence of BCL2L11 polymorphism on osteonecrosis during treatment of childhood acute lymphoblastic leukemia
    Plesa, Maria
    Gagne, Vincent
    Glisovic, Sanja
    Younan, Melissa
    Sharif-Askari, Bahram
    Laverdiere, Caroline
    Alos, Nathalie
    Leclerc, Jean-Marie
    Sallan, Stephen E.
    Neuberg, Donna
    Kutok, Jeffery L.
    Silverman, Lewis B.
    Sinnett, Daniel
    Krajinovic, Maja
    PHARMACOGENOMICS JOURNAL, 2019, 19 (01): : 33 - 41
  • [10] BCL2L11 Is Associated With Kawasaki Disease in Intravenous Immunoglobulin Responder Patients
    Kwon, Young-Chang
    Kim, Jae-Jung
    Yun, Sin Weon
    Yu, Jeong Jin
    Yoon, Kyung Lim
    Lee, Kyung-Yil
    Kil, Hong-Ryang
    Kim, Gi Beom
    Han, Myung-Ki
    Song, Min Seob
    Lee, Hyoung Doo
    Ha, Kee Soo
    Sohn, Sejung
    Hong, Young Mi
    Jang, Gi Young
    Lee, Jong-Keuk
    CIRCULATION-GENOMIC AND PRECISION MEDICINE, 2018, 11 (02):
12345